Management ChangeMay 5, 2026, 12:36 PM
Apimeds Pharmaceuticals Appoints Sungjoon Chae as Co-CEO
AI Summary
Apimeds Pharmaceuticals US, Inc. announced the appointment of Sungjoon Chae as its Co-Chief Executive Officer, effective May 4, 2026. Mr. Chae was nominated by a company stockholder. His compensation arrangements are yet to be determined and will be disclosed once finalized. Sungjoon Chae brings extensive experience as an architect and urban designer, specializing in large-scale real estate development and urban regeneration across South Korea and the United States.
Key Highlights
- Sungjoon Chae appointed Co-Chief Executive Officer of Apimeds Pharmaceuticals US, Inc.
- Appointment became effective on May 4, 2026.
- Mr. Chae was nominated by a stockholder of the company.
- His compensation arrangements have not yet been finalized.
- Sungjoon Chae holds a Master of Architecture in Urban Design from Harvard University (2013).
- He specializes in large-scale real estate development and urban regeneration.